bioRxiv Science⌕ Search

bioRxiv · 10.1101/2025.09.26.678791

Lantana camara leaf extract-mediated suppression of DNA methyltransferase 1 promotes G0/G1 cell cycle arrest and apoptosis, and impedes migration in MDA-MB-231 triple-negative breast cancer cells

Abstract

BackgroundTriple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer with limited therapeutic options and poor prognosis. DNA methyltransferase 1 (DNMT1) maintains aberrant silencing of tumor suppressor genes, contributing to cancer progression. Our previous work demonstrated that Lantana camara leaf extract induces G0/G1 arrest and apoptosis, while inhibiting migration in MDA-MB-231 TNBC cells (Pal et al., 2024). PurposeThis study investigated the role of DNMT1 in mediating the anticancer effects of Lantana camara extract. Study DesignAn in vitro experimental study was performed using MDA-MB-231 TNBC cells. MethodsCells were treated with the extract, and the expression of DNMT1 was analyzed at the mRNA and protein levels. Expression of tumor suppressor genes was assessed at mRNA level. Functional assays were conducted following DNMT1 overexpression to examine its impact on extract-induced effects. Expression of methyl-CpG binding domain protein 2 (MBD2), histone deacetylase 1 (HDAC1), and histone deacetylase 2 (HDAC2) was evaluated at the mRNA level. ResultsThe extract significantly downregulated DNMT1, resulting in the reactivation of multiple tumor suppressor genes. Overexpression of DNMT1 counteracted the extract-induced reduction in cell viability, reduced G0/G1 arrest, attenuated apoptosis, and enhanced migratory capacity, while suppressing the mRNA expression of tumor suppressor genes. Additionally, the extract downregulated the mRNA expression of MBD2, HDAC1, and HDAC2, suggesting broader modulation of epigenetic regulators. ConclusionSuppression of DNMT1 is a central mechanism underlying the anticancer activity of Lantana camara extract. These findings highlight its potential as a natural epigenetic modulator and a promising therapeutic candidate for TNBC.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Sanyal, S., Pal, A., SENGUPTA, T. K.. 2025-09-29. Lantana camara leaf extract-mediated suppression of DNA methyltransferase 1 promotes G0/G1 cell cycle arrest and apoptosis, and impedes migration in MDA-MB-231 triple-negative breast cancer cells. https://doi.org/10.1101/2025.09.26.678791

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

Epigenetic progression of pancreatic cancer to aggressive subtypes involves alternate routes of lineage reprogramming in subtype-intermediate progenitor cells

Pancreatic ductal adenocarcinoma (PDAC) progression involves malignant cell state plasticity. Epigenetic changes underlie this plasticity, yet the PDAC cis-regulatory landscape remains understudied. To address this, we profiled 33 primary tumors and 7 metastases from 39 patients with single-cell ATAC-seq, paired with 10 single-cell RNA-seq profiles. We found that epigenetic GATA6+/KRT17+ co-accessibility identifies a classical-basal subtype-intermediate progenitor state (SIP) associated with better clinical outcomes. SIP cells display limited epigenetic reprogramming from premalignant epithelium and retain gastric-intestinal differentiation reminiscent of neoplastic precursors. Lineages without GATA6+/KRT17+ co-accessibility exhibit greater lineage and epithelial-mesenchymal plasticity. Classical PDACs that repress basal gene accessibility activate neural-like progenitor (NRP) and tuft lineage enhancers, whereas basal committed tumors display esophageal transdifferentiation. Compared to SIP, classical-NRP and basal committed tumors have poorer outcomes, and show distinct PD-1/PD-L1 immune proteomic phenotypes and prognostic myofibroblast epigenetic states, respectively. Our work reveals links between lineage reprogramming, EMT, and epigenetic progression in human PDAC.

cancer biology↗

Tissue resident CD4+ memory T-cells mark response to immune checkpoint inhibition in high-grade glioma

Background: Immune checkpoint inhibitors (ICI) are efficacious in many solid tumors, but response in glioma is restricted to a small subgroup. The determinants of response and resistance to ICI remain poorly understood. Methods: Here we exploit a syngeneic hypermutated high-grade glioma model with dichotomous response to combined PD-1 and CTLA-4 inhibition to unravel determinants of tumor-infiltrating T-cells driving response. Tumor-infiltrating T-cells from ICI-responsive and non-responsive tumors were analyzed by single-cell RNA and T-cell receptor sequencing and tumor-reactive T-cell receptor clonotypes were functionally validated to characterize their transcriptional phenotypes. We verify our findings in IDH1 wildtype glioblastoma patients treated with neoadjuvant pembrolizumab. Results: ICI response was associated with intratumoral clonal expansion of tumor-reactive cytotoxic T-cells and increased infiltration of CXCR6+ CD4+ tissue resident memory T-cells (Trm). CD4 stem-like memory T-cells in responding tumors demonstrated elevated interferon responses, following trajectories toward clonally expanded Trm, versus trajectories toward exhaustion in non-responsive tumors. In responsive tumors, CD4+ Trm interacted with infiltrating CXCR3+ tumor-reactive and clonally expanded, yet transcriptionally versatile cytotoxic T-cells. Probing the post neoadjuvant ICI high-grade glioma patient tissue dataset, we confirmed increased CXCR6 expression in CD4+ T cells and the association of CD4+ Trm with prolonged overall survival. Conclusion: These findings identify CD4 tissue-resident memory T-cells as determinants of ICI response in IDH1 wildtype high-grade glioma and warrant their further investigation to improve immunotherapy outcomes.

cancer biology↗

Low-dose doxorubicin drives caveolin-1 depended re-epithelialization of breast cancer cells as a mechanism of cancer plasticity

Breast cancer progression is driven by dynamic changes in epithelial plasticity, membrane organization, and intracellular signaling, yet the effects of sustained low-dose chemotherapy on these processes remain poorly understood. Here, we investigated the impact of prolonged low-dose doxorubicin on membrane remodeling, epithelial phenotype, membrane-associated Ras lipid-anchor localization, and autophagy in mesenchymal-like MDA-MB-231 breast cancer cells. Low-dose doxorubicin significantly increased Caveolin-1 expression and enhanced E-cadherin protein levels, accompanied by a transition toward a more compact epithelial-like morphology with increased cell-cell contacts. Live-cell imaging demonstrated a significant reduction in the membrane-to-cytoplasm fluorescence ratio of the lipid-anchored GFP-tH probe, indicating redistribution from the plasma membrane to the cytoplasm following treatment. Analysis of autophagy-related proteins revealed decreased LC3-I together with increased LC3-II, ATG5, and p62 expression, consistent with autophagosome accumulation and impaired autophagic flux. Collectively, our findings demonstrate that low-dose doxorubicin promotes extensive remodeling of plasma membrane organization, epithelial plasticity, membrane-associated lipid-anchor localization, and autophagy. This integrated response reveals previously unrecognized links between membrane architecture, Ras membrane association, and autophagy during phenotypic reprogramming of breast cancer cells, providing mechanistic insight into cellular adaptations elicited by sub-cytotoxic doxorubicin exposure.

cancer biology↗